Wells Fargo & Company MN Invests $185,000 in Aptinyx Inc (APTX)

Aptinyx logo Wells Fargo & Company MN bought a new position in Aptinyx Inc (NASDAQ:APTX) during the third quarter, according to its most recent filing with the SEC. The firm bought 6,383 shares of the company’s stock, valued at approximately $185,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Strs Ohio bought a new position in Aptinyx during the 3rd quarter valued at $110,000. Northern Trust Corp bought a new stake in shares of Aptinyx during the 2nd quarter worth $304,000. BlackRock Inc. bought a new stake in shares of Aptinyx during the 2nd quarter worth $967,000. Victory Capital Management Inc. increased its holdings in Aptinyx by 14.8% in the 3rd quarter. Victory Capital Management Inc. now owns 806,989 shares of the company’s stock worth $23,371,000 after acquiring an additional 104,297 shares during the last quarter. Finally, Millennium Management LLC purchased a new stake in Aptinyx in the 2nd quarter worth about $2,615,000. Institutional investors own 62.59% of the company’s stock.

A number of research analysts have weighed in on APTX shares. Cantor Fitzgerald started coverage on Aptinyx in a report on Wednesday, November 14th. They set an “overweight” rating and a $40.00 target price for the company. JPMorgan Chase & Co. lowered Aptinyx from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $30.00 to $8.00 in a report on Thursday, January 17th. Leerink Swann reduced their target price on Aptinyx from $35.00 to $22.00 and set an “outperform” rating for the company in a report on Thursday, January 17th. Zacks Investment Research upgraded Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 price target for the company in a research report on Monday, January 21st. Finally, BMO Capital Markets dropped their price target on Aptinyx to $18.00 and set an “outperform” rating for the company in a research report on Friday, January 18th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $18.80.

In other news, CFO Ashish Khanna purchased 10,000 shares of Aptinyx stock in a transaction that occurred on Friday, January 18th. The shares were bought at an average cost of $5.45 per share, with a total value of $54,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, Director Robert J. Hombach purchased 25,000 shares of Aptinyx stock in a transaction that occurred on Friday, January 25th. The stock was purchased at an average cost of $5.53 per share, for a total transaction of $138,250.00. The disclosure for this purchase can be found here . Insiders have bought 36,050 shares of company stock worth $198,284 over the last three months.

NASDAQ:APTX traded up $0.13 during mid-day trading on Thursday, reaching $5.70. The stock had a trading volume of 334,447 shares, compared to its average volume of 489,297. Aptinyx Inc has a one year low of $4.70 and a one year high of $32.25.

Aptinyx (NASDAQ:APTX) last announced its quarterly earnings data on Tuesday, November 13th. The company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.01) by $0.58. The company had revenue of $0.94 million during the quarter, compared to the consensus estimate of $1.10 million. On average, equities analysts forecast that Aptinyx Inc will post -2.55 EPS for the current fiscal year.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. Institutional Ownership by Quarter for Aptinyx (NASDAQ:APTX) Receive News & Ratings for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptinyx and related companies with MarketBeat.com’s FREE daily email newsletter .

Click Here to Continue...


Add a Comment

Your email address will not be published. Required fields are marked *